Neurocrine Biosciences, Inc. (NBIX) on Decifer

Decifer ranks NBIX number 255 of 269 tracked names on durable business quality.

Why it ranks here

• Sales are growing about 21% a year, faster than 69 in 100 companies we measure.
• It keeps about 26 cents of every sales dollar as cash, safer than 89 in 100 companies we measure.
• It earns about 11% a year on the money put into the business, better than 59 in 100 companies we measure.
• It costs about 21 times its yearly profit; the middle of its industry is 21. Cheaper than 47 in 100 companies we measure, against their own industries.

The current read

The evidence on NBIX lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Neuroscience & Mental Health Access: Growing recognition and destigmatization of mental health, combined with new neuro-targeted drugs and neurostimulation devices, is expanding demand for both treatment capacity and therapies.

Read the full NBIX research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.